Kymera CEO sells 80K shares under 10b5-1 plan
Kymera Therapeutics CEO Nello Mainolfi reported a mix of option exercises and share sales in the company’s stock.
Rhea-AI Filing Summary
Kymera Therapeutics CEO Nello Mainolfi reported a mix of option exercises and share sales in the company’s stock. On July 1, 2026, he exercised stock options for 80,000 shares of common stock at an exercise price of $2.08 per share, converting a derivative position into regular shares.
That same day, he sold 80,000 shares of common stock in five open-market transactions at weighted average prices ranging from about $112.28 to $116.63 per share. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and notes that he continues to hold a substantial direct equity stake in Kymera.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 80,000 shares ($9.06M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Mainolfi Nello
Role
Chief Executive Officer
Sold
80,000 shs ($9.22M)
Approx. gross sale proceeds
$9.22M
Approx. exercise cost
$166K
Approx. pre-tax spread
$9.06M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 80,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 80,000 | $2.08 | $166K |
| Sale | Common Stock | 1,883 | $112.8046 | $212K |
| Sale | Common Stock | 6,626 | $113.9758 | $755K |
| Sale | Common Stock | 24,105 | $114.9555 | $2.77M |
| Sale | Common Stock | 44,050 | $115.6883 | $5.10M |
| Sale | Common Stock | 3,336 | $116.559 | $389K |
Holdings After Transaction:
Stock Option (Right to Buy) — 135,559 contracts (Direct);
Common Stock — 666,568 shares (Direct)
Footnotes (8)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
- F2. This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.28 to $113.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.36 to $114.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.29 to $115.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 to $116.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.29 to $116.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The shares underlying this stock option are fully vested and exercisable.
Key Figures
Shares sold: 80,000 shares
Sale price range: $112.28–$116.63 per share
Option exercise shares: 80,000 shares
+4 more
7 metrics
Shares sold
80,000 shares
Total common shares sold across five open-market trades on July 1, 2026
Sale price range
$112.28–$116.63 per share
Weighted average price ranges for the reported open-market sales
Option exercise shares
80,000 shares
Common shares acquired via stock option exercise on July 1, 2026
Option exercise price
$2.08 per share
Exercise price of stock options converted into common stock
Net share change from trades
80,000 shares
Net-sell shares reported in transaction summary
Rule 10b5-1 plan date
March 24, 2026
Date of pre-arranged trading plan governing these transactions
ESPP shares
373 shares
Shares acquired under Kymera’s employee stock purchase plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, employee stock purchase plan, stock option, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase plan financial
"This number includes 373 shares acquired under the Registrant's employee stock purchase plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
stock option financial
"The shares underlying this stock option are fully vested and exercisable"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kymera Therapeutics (KYMR) CEO Nello Mainolfi report in this Form 4?
He reported exercising stock options for 80,000 Kymera shares and selling 80,000 common shares in open-market transactions. The activity reflects both acquiring shares via option exercise and disposing of shares through sales on the same date.
What stock options did the Kymera (KYMR) CEO exercise in this filing?
He exercised stock options covering 80,000 shares of Kymera common stock at an exercise price of $2.08 per share. A related footnote states the underlying option shares are fully vested and exercisable, and the derivative position is now converted into common stock.
What does the Form 4 say about the CEO’s remaining Kymera (KYMR) holdings?
The Form 4 shows updated share balances after each transaction and indicates the CEO continues to hold a significant number of Kymera common shares directly. It also notes that 373 shares were acquired through the company’s employee stock purchase plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
